Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) announced that its Board’s Compensation Committee granted stock options to purchase an aggregate of 85,500 common shares to five newly hired employees on June 1, 2026.
The options, issued under the 2025 New Hire Inducement Plan, will vest over four years and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction – OBIO
In the Jun 3 session, OBIO declined 1.28%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | Conference participation | Neutral | +2.3% | Announced participation in Jefferies Global Healthcare Conference with webcast access. |
| May 12 | Earnings and updates | Neutral | +0.0% | Reported Q1 2026 results, cash runway into Q4 2027, and trial progress. |
| May 12 | Trial timeline update | Positive | +3.8% | Updated BACKBEAT pivotal trial timelines and FDA-approved sample size reduction. |
| May 6 | Strategic financing | Positive | +2.5% | Received $15M tranche from Ligand, bringing capital from Ligand to $40M. |
| May 6 | Strategic financing | Positive | +2.5% | Received $20M from Medtronic under financing agreement to support BACKBEAT Trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news — especially financing and pivotal trial updates — has generally coincided with modestly positive price reactions, suggesting the stock often reacts constructively to strategic and clinical milestones.
Over the last few months, Orchestra BioMed has focused on financing and pivotal trial execution. On May 6, it reported $35 million in strategic capital from Medtronic and Ligand, tied to advancing AVIM Therapy and Virtue SAB, with shares rising modestly. Earlier in May, updates on the pivotal BACKBEAT Trial and a second FDA Breakthrough Device Designation also saw positive reactions. The current inducement option grants fit into this broader pattern of routine corporate and governance activity around a growing clinical program.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 85,500 shares of the Company’s common stock to five newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options granted to each new employee will vest over a four-year period.
Orchestra Biomed is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com
